Cat. No. 2155
Chemical Name: 2-Nitro-N-[[trans-4-[[[(1,2,3,4-tet
Biological ActivitySelective, non-peptide competitive NPY Y5 antagonist. Ki values are 8.0 and 16032 nM at human recombinant Y5 and Y1 receptors respectively. Potently antagonizes NPY inhibition of forskolin-stimulated cAMP. Displays some affinity for cloned human D2 and α2C receptors (Ki values are 63 and 100 nM respectively).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Islam et al (2002) Discovery of potent and selective small molecule NPY Y5 receptor antagonists. Bioorg.Med.Chem.Lett. 12 1767. PMID: 12067557.
If you know of a relevant reference for NTNCB hydrochloride please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses NTNCB hydrochloride from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: NTNCB hydrochloride, supplier, Potent, selective, non-peptidic, Y5, antagonists, Neuropeptide, Y, Receptors, NPY, neuropeptides, Tocris Bioscience, NPY Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Negative control for ELA-32 (Cat.No.6291).ELA-32 (human)
Potent, high affinity apelin receptor agonist; stimulates angiogenesisParathyroid hormone (1-34) (bovine)
Parathyroid hormone (PTH) receptor agonist.Parathyroid hormone (1-34) (rat)
Parathyroid hormone (PTH) receptor agonistPeptide YY (3-36) human
NPY Y2 receptor agonistELA-14 negative control
Negative control for ELA-14 (Cat.No.6293).ELA-14 (human)
Potent apelin (APJ) receptor agonistRetrobradykinin
Reverse analog of BradykininTASP 0390325
Potent and selective V1B receptor antagonist; orally bioavailable
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.